Clinical trials: Oesophageal Adenocarcinoma, active
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 751 sites in United States
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Stomach Cancer Stage IV, Esophagus Cancer
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
This is a single arm, open-label, phase II trial investigating the combination of ivonescimab with standard FOLFOX chemotherapy in 1L therapy for HER2- GEA.
- Conditions
- Stomach Cancer Stage IV, Esophagus Cancer, Stomach Cancer
- Trial name
- NCT07070466
- Testing
- Ivonescimab, 5-Fluorouracil, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Pancreatic Adenocarcinoma, Cholangiocarcinoma
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
This study is a single-center, single-arm, open-label, phase II clinical trial designed to evaluate the efficacy and safety of Paclitaxel Polymeric Micelles for Injection for the treatment of patients with advanced pancreatic…
- Conditions
- Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Stomach Cancer
- Trial name
- NCT06199895
- Testing
- Paclitaxel Polymeric Micelles for Injection
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Liu Huang
Gastric-Esophageal Cancer
Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer
The goal of this clinical trial is to assess if circulating tumor DNA, as assessed by Signatera tumor-informed MRD assay, can guide de-escalation of adjuvant therapy in patients with resectable Stage II-IVa…
- Trial name
- SIGNAL GEC-101 (NCT07565857)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 1,000 people
- Sponsor
- Natera, Inc.
Early Gastric Cancer, Adenocarcinoma of the Stomach
SPADE Clinical Trial.
Purpose: This multicenter, prospective, single-arm phase 2 clinical trial aims to evaluate the safety, feasibility, and clinical outcomes of the SPADE operation (Spade-Shaped Anastomosis) in patients undergoing laparoscopic or…
- Conditions
- Early Gastric Cancer, Adenocarcinoma of the Stomach, Proximal Gastric Cancer, SPADE Operation
- Trial name
- SPADE (NCT07892183)
- Testing
- Spade-Shaped Anastomosis after Laparoscopic or Robotic Proximal Gastrectomy Using Double Suture Anchoring between the Posterior Wall of the Esophagus and the Anterior Wall of the Stomac
- Where
- South Korea
- Volunteers
- 159 people
- Sponsor
- National Cancer Center, Korea
Oesophageal Cancer, Gastric Cancer
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
The aim of the project is to demonstrate superior detection ratio of [18F]AlF-FAPI-74 PET/CT compared to [18F]FDG PET/CT or conventional imaging in treatment-naïve, newly diagnosed patients with oesophagogastric adenocarcinoma…
- Conditions
- Oesophageal Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma, FAP
- Trial name
- FAPIDO (NCT06782412)
- Testing
- [18F]AlF-FAPI-74 PET/CT
- Where
- 3 sites in Belgium
- Volunteers
- 109 people
- Sponsor
- KU Leuven
Metastatic Gastro-esophageal Adenocarcinoma
Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy
The goal of this clinical trial is to evaluate if bemarituzumab in combination with different standard of care chemotherapies enhance tumor response in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the…
- Trial name
- NCT06680622
- Testing
- bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil
- Where
- 35 sites in Germany
- Volunteers
- 126 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Non Small Cell Lung Cancer, Cervical Cancer
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab.
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT07218003
- Testing
- RNDO-564, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 149 people
- Sponsor
- Rondo Therapeutics
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.
Gastric Adenocarcinoma, Adenocarcinoma of the Esophagogastric Junction
Sino-Russian Comparison of Outcomes After Proximal Gastrectomy With Double-Tract Reconstruction
This two-center retrospective observational cohort study compares Chinese and Russian patients who underwent curative proximal gastrectomy with double-tract reconstruction for proximal gastric adenocarcinoma or Siewert type…
- Trial name
- RUSCHI-DTR (NCT07800819)
- Testing
- Proximal gastrectomy with double-tract reconstruction
- Where
- 2 sites in China, Russia
- Volunteers
- 250 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Urinary Bladder Cancer, Melanoma
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung…
- Conditions
- Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT03132922
- Testing
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
- Where
- 11 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- USWM CT, LLC
Advanced Solid Tumors
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.
- Trial name
- NCT05954312
- Testing
- VVD-130037, Docetaxel, Paclitaxel
- Where
- 26 sites in United States, South Korea and 1 more
- Volunteers
- 290 people
- Sponsor
- Vividion Therapeutics, Inc.
Gastroesophageal-junction Cancer, Esophageal Cancer
Registry for Esophageal and Gastroesophageal Junction Cancer
The purpose of this registry study is to create a database-a collection of information-for better understanding standard treatments for esophageal and Gastroesophageal Junction Cancer/GEJ cancer.
- Trial name
- NCT06558786
- Testing
- EORTC QLQ-C30 questionnaire, QLQ-OGS25 questionnaire
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
The goal of this study is to learn about of the research study drug, telomelysin (OBP-301), in combination with pembrolizumab in advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer.
- Conditions
- Esophageal Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT06340711
- Testing
- OBP-301, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Weill Medical College of Cornell University
OESOPHAGO-GASTRIC CARCINOMA
Hypoxia Driven Metabolic Response in Oesophagogastric Adenocarcinoma
Oesophagogastric Cancer and Hypoxia: Oesophagogastric cancer is a significant global burden, with 1.7 million new cases per year. It is well known that survival from oesophagogastric cancer is poor.
- Trial name
- HYDRA (NCT06669663)
- Testing
- Pimonidazole hydrochloride (Hypoxyprobe™-1)
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Imperial College London
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04389632
- Testing
- sigvotatug vedotin, pembrolizumab, cisplatin
- Where
- 158 sites in United States, France and 5 more
- Volunteers
- 1,006 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Barrett Esophagus, Barretts Esophagus With Dysplasia
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
The purpose of this research study is to learn about the best approach to sample patients with known or suspected Barrett's esophagus (BE) by comparing the standard Seattle biopsy protocol to sampling using wide area…
- Conditions
- Barrett Esophagus, Barretts Esophagus With Dysplasia, Esophageal Adenocarcinoma
- Trial name
- SWAT-BE (NCT05530343)
- Testing
- Seattle protocol, WATS3D brushings
- Where
- 14 sites in United States
- Volunteers
- 2,298 people
- Sponsor
- University of Colorado, Denver
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) with or without nivolumab to the effect of modified fluorouracil, leucovorin calcium, and…
- Conditions
- Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT05677490
- Testing
- Fluorouracil, Leucovorin Calcium, Oxaliplatin
- Where
- 802 sites in United States, Puerto Rico
- Volunteers
- 382 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Oesophageal Adenocarcinoma, Tumor Microenvironment
Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy
The primary objective of this study is to investigate whether two weeks of metformin treatment can activate the tumour microenvironment in patients with stage II and III oesophageal adenocarcinomas.
- Trial name
- MEMENTO (NCT06687876)
- Testing
- Metformin
- Where
- 2 sites in Netherlands
- Volunteers
- 14 people
- Sponsor
- Amsterdam UMC, location VUmc